Cobra Biologics and Pharmaceutical Services Cobra provides a comprehensive biologics and pharmaceuticals service offering, with multi-functional and experienced project teams nurturing customers’ products from pre-clinical through to clinical and commercial manufacture within GMP approved facilities. Latest News View all Links & Downloads: Cobra Articles 3rd Jun 2019 Cobra Biologics Expands DNA Vaccines, Gene And Immunotherapy Production In Sweden With €20m Plant 29th Mar 2019 Room For Improvement: Tackling Sub-Optimal Downstream Process Unit Operations For Viral Vectors 22nd Mar 2019 HQ Plasmid Slots Now Available Our High Quality (HQ) offering adopts features of Cobra’s GMP manufacture with a 6 week delivery time. Find Out More & Get In Touch Today Cobra Biologics Receives the Queen’s Award for Enterprise in International Trade The UK’s most prestigious business award granted in recognition of outstanding achievement in the export of services for gene and immunotherapy products. Find Out More Our Awards Get In Touch Speak to a member of our expert team and arrange to take a tour of our GMP facilities in the UK and Sweden. Contact Us About Cobra Biologics Cobra Biologics is a leading international contract development and manufacturing organisation (CDMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply. 2 GMP approved facilities 320+ products released for clinical trials 18 Countries serviced @CobraBiologics yesterday Check out @pharmaphorum's latest article on Cobra's partnership with @PallCorporation and @CGTCatapult to investiga… https://t.co/vrq6omMdgz 3 days ago We're looking forward to seeing everyone at @_BSGCT this week! Visit our website to pre-arrange a meeting with our… https://t.co/QJYNP9lBeK 7 days ago A great couple of days in Stockholm moving Advanced Therapy collaborations forward in Sweden 🇸�@CobraBiologicsipic.twitter.com/qm1iO6KjD6jD6 Sign up to receive news and more Keep up to date with the latest news from Cobra Biologics Newsletter signup Name Email
Cobra Biologics Expands DNA Vaccines, Gene And Immunotherapy Production In Sweden With €20m Plant 29th Mar 2019
Room For Improvement: Tackling Sub-Optimal Downstream Process Unit Operations For Viral Vectors 22nd Mar 2019